A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis
Latest Information Update: 11 Dec 2023
At a glance
- Drugs HS-10374 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 30 Nov 2023 Status changed from not yet recruiting to recruiting.
- 13 Oct 2023 New trial record